← boardnext 2027-09
AGEN
Agenus Inc.distress 7/10 · high distress / dilution risk$5.65+2%today-20% from 52w high
Oncology 2
Lead: Advanced Melanoma · target CTLA-4 · est. market ~$10B (approx, global)
Revenue
$34M
Liquidity
$50M
Runway
0.6 yrs
Shares 1y
+31%
Price & events
+67.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.2%
1D
+13.0%
1W
+84.0%
1M
+50.3%
3M
+74.4%
6M
-6.9%
1Y
-18.2%
2Y
-94.9%
5Y
-91.1%
All
Overview
- Market Cap
- $235.28M
- Enterprise Value
- $230.48M
- Volume
- 150.19K
- 52 Week Range
- $2.77 – $7.06
- Total Shares
- 41.64M
- Float Shares
- 37.19M
- Short %
- 14.58%
- % Held by Insiders
- 6.72%
- % Held by Institutions
- 23.70%
- RVOL
- 0.02x
- Beta
- 1.55
Pipeline stages · 2 programs
Botensilimab, Balstilimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AGEN2034, AGEN1884PD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 2 | Botensilimab, Balstilimab | Metastatic Colorectal Cancer | — | active not recruiting |
| 2028-02 Estimated 50% readout ~2028-03-17 | Phase 2 | Botensilimab, Balstilimab | Advanced Melanoma | — | active not recruiting |
| 2026-01-05 | Phase 2 | Botensilimab, Gemcitabine, Nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma | 81 | completed |
| 2025-03-26 | Phase 2 | AGEN2034, AGEN1884 | Cervical Cancer | 211 | terminated |
Catalyst news & presentations · 4
- 2026Guided 40%trial initiationsecondaryPhase 3BOT+BAL · BATTMAN Phase 3 trial initiated with sites activated for patient enrollment.SEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-01-15partnershipBOT+BAL · Closed strategic collaboration with Zydus, receiving $75M upfront cash and $16M equity investment for manufacturing assets and India/Sri Lanka license.SEC 8-K
- 2025-06-03partnershipBOT/BAL · Asset purchase, $16M equity investment, and exclusive license agreement with Zydus for India and Sri Lanka.SEC 8-K
Approved drugs (4)
- POKONZAPOTASSIUM CHLORIDE2015 · Prescription
- TIVORBEXINDOMETHACIN2014 · Discontinued
- VERDESODESONIDE2006 · Discontinued
- HYCODANHOMATROPINE METHYLBROMIDE1943 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $30 (+431% upside) · 1 analysts
- 2026-07-13HC Wainwright & Co.Buy
- 2025-09-10HC Wainwright & Co.Buy
- 2025-08-28HC Wainwright & Co.Buy
- 2025-06-04BairdNeutral
- 2025-06-04HC Wainwright & Co.Neutral → Buy
- 2025-05-13HC Wainwright & Co.Neutral
Competitors — CTLA-4
- none identified
Recent news
- 2026-07-23Agenus: More Shares, Fresh Starts, And Executive Pay Under The Microscope Sportitalia (bXVgSS8OPp) - Mshale
- 2026-07-20RA Capital and affiliates (NASDAQ: AGEN) disclose 9.99% beneficial ownership in Agenus - Stock Titan
- 2026-07-20Agenus (AGEN) Registration filing Summary - Quartr
- 2026-07-20Agenus (NASDAQ: AGEN) registers 2.13M previously issued shares for resale - Stock Titan
- 2026-07-20Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 - BioSpace
- 2026-07-19Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 - 뉴스와이어
- 2026-07-18Agenus Inc. - AGEN Stock Chart Technical Analysis For 03-09-2020 Giro D'italia (XPKerZ1996) - Mshale
- 2026-07-17Agenus Inc. (AGEN) investors disclose 4.53M-share stake capped at 9.99% - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.